Project Grant R00HL163411
Award Date
9/16/24
Completion Date
8/31/27
Dollars Obligated
$507K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $331,344 to The Leland Stanford Junior University to conduct research on the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its impact on smooth muscle cell phenotypic modulation. The goal is to determine how PRDM16, an epigenetic modifier, regulates the transition of smooth muscle cells to a protective "fibromyocyte"...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,406,736 to the Palo Alto Veterans Institute for Research (PAVIR) to conduct research aimed at understanding the mechanisms and impact of coronary artery patterning. The overarching goal is to identify pathways that could stimulate coronary artery growth and collateralization, with the potential to develop new therapies to improve outcomes for individuals with...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $802,762 to The University of Texas Southwestern Medical Center to interpret the impact of coding and non-coding genetic variants on congenital heart disease (CHD) through the analysis of cardiac gene regulatory networks. The key objectives are to: 1) Define the transcription factors and gene regulatory networks involved in human cardiac development; 2) Characterize...
This Project Grant award of $540,856 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the gene regulatory networks that control endocardial-specific gene expression. The key objectives are to: 1) Identify transcriptional regulators of endocardial-restricted gene expression, 2) Determine how valve-restricted gene expression is achieved, and 3) Define the regulation and function of the SLC16A2 gene during heart injury...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of scalable methods to identify causal genetic variants, relevant cell types, and target genes underlying cardiovascular disease (CVD). The grantee, New York Genome Center, Inc. (NYGC), will leverage multi-ancestry genome-wide association studies (GWAS) and apply innovative techniques like CRISPR screens,...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to investigate the genetic and environmental factors contributing to the development of complex lymphatic anomalies (CLAs), a group of rare and debilitating vascular diseases. The $508,436 award to The University of Texas Southwestern Medical Center will test the hypothesis that CLAs require both a genetic mutation and a permissive lymphangiogenic...
This Project Grant award for $715,180.00, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to understand the epigenetic regulation of trained immunity in thoracic aortic aneurysms and dissections (ATAAD). The primary objectives are to determine the sites and epigenetic signatures of immune cell training, as well as the causal role of the STING-IRF3/IRF4 signaling pathway in driving pro-inflammatory macrophage phenotypes...
This Project Grant award in the amount of $121,500.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to The University of Texas MD Anderson Cancer Center. The goal of this research project is to investigate the molecular mechanisms by which environmental and lifestyle risk factors influence cardiovascular traits and the risk of cardiovascular disease. The researchers will leverage large-scale multi-omics...
The University of Connecticut Health Center received a $615,006 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective December 15, 2024 through November 30, 2028, will fund research to reclassify and determine the pathogenicity and pathophysiology of variants of unknown significance in the TNNT2 gene, which encodes an essential component of the cardiac sarcomere. Key research activities...